This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Xopenex HFA MDI

Sumitomo Dainippon Pharma Co., Ltd.

Drug Names(s): hydrofluoroalkane (HFA), Xopenex MDI (metered-dose inhaler)

Description: As of its October 2009 acquisition of Sepracor (renamed Sunovion), Dainippon now reports revenue for Xopenex HFA and the inhalation product under Xopenex.

The active ingredient of Xopenex, levalbuterol, is a single isomer formulation of the widely prescribed racemic albuterol. It binds to human beta adrenergic receptors on smooth muscle cells of airways. Activation of the beta adrenergic receptors results in the relaxation of the airways. As well as being available as a metered dose inhaler using an HFA propellant, Xopenex is available as a solution to use with a nebulizer (Xopenex).

Deal Structure: Sepracor and 3M
Under a supply agreement with 3M, Sepracor is obligated to pay a combination of a fixed price per unit of product purchased and a percentage royalty based on net sales of Xopenex HFA MDI.

Graceway and 3M US, Canada, Latin America Pharmaceutical Operations
In December 2006, Graceway Pharmaceuticals acquired 3M's pharmaceuticals operations in the United States, Canada, and Latin America. Under the agreement, Graceway Pharmaceuticals will acquire exclusive regional marketing and intellectual property rights to 3M's branded pharmaceuticals.

Dainippon Sumitomo Pharma and Sepracor
In September 2009, Dainippon Sumitomo Pharma (DSP) and Sepracor announced that they entered into a definitive agreement pursuant to which DSP will acquire Sepracor for approximately $2.6 billion through a cash tender offer of $23.00 per share. The acquisition was completed in October 2009.

Medicis and Graceway
In November 2011, Medicis...See full deal structure in Biomedtracker

Partners: Valeant Pharmaceuticals International, Inc.


Xopenex HFA MDI News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug